Innovation ECDGfRa: Population ageing in Europe facts, implications and policies. Outcomes of EU-funded research. 2014.
Google Scholar
Yazici Y, Paget SA. Elderly-onset rheumatoid arthritis. Rheum Dis Clin N Am. 2000;26(3):517–26.
Article
CAS
Google Scholar
Kato E, Sawada T, Tahara K, Hayashi H, Tago M, Mori H, Nishino J, Matsui T, Tohma S. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis. 2017;20(7):839–45.
Article
Google Scholar
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheumatism. 1998;41(1):58–67.
Article
CAS
Google Scholar
HB BA, Delrieu F. Enquete nationale sur les arthrites réactionnelles de la Societe Francaise de Rhumatologie. Rev Rhum. 1983;50(11):733–43.
Google Scholar
Murata K, Ito H, Hashimoto M, Nishitani K, Murakami K, Tanaka M, Yamamoto W, Mimori T, Matsuda S. Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int J Rheum Dis. 2019;22(6):1084–93.
Article
CAS
Google Scholar
Tan TC, Gao X, Thong BYH, Leong KP, Lian TY, Law WG, Kong KO, Howe HS, Chng HH, Koh ET. Comparison of elderly-and young-onset rheumatoid arthritis in an Asian cohort. Int J Rheum Dis. 2017;20(6):737–45.
Article
CAS
Google Scholar
Montilla C, Del Pino-Montes J, Collantes-Estevez E, Font P, Zarco P, Mulero J, Gratacós J, Rodríguez C, Juanola X, Fernández-Sueiro JL. Clinical features of late-onset ankylosing spondylitis: comparison with early-onset disease. J Rheumatol. 2012;39(5):1008–12.
Article
Google Scholar
Toussirot E, Wendling D. Late-onset ankylosing spondylitis and related spondylarthropathies. Drugs Aging. 2005;22(6):451–69.
Article
CAS
Google Scholar
Toussirot É. Late-onset ankylosing spondylitis and spondylarthritis. Drugs Aging. 2010;27(7):523–31.
Article
CAS
Google Scholar
Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006;33(2):234–43.
CAS
PubMed
Google Scholar
Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24(3):239–54.
Article
CAS
Google Scholar
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, Watson KD, Lunt M, Consortium BCC, Symmons DP. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2010;50(1):124–31.
Article
Google Scholar
Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheumatism. 2010;62(1):22–32.
Article
CAS
Google Scholar
Radovits BJ, Kievit W, Fransen J, van de Laar MAFJ, Jansen TL, van Riel PLCM, Laan RFJM. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68(9):1470.
Article
CAS
Google Scholar
Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, Arthritis PotSCQMPfR. Tolerance and effectiveness of anti–tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Care Res. 2007;57(4):679–85.
Article
Google Scholar
Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295.
Article
Google Scholar
Sanchez-Piedra C, Miguel MVH, Manero J, Roselló R, Sánchez-Costa JT, Rodríguez-Lozano C, Campos C, Cuende E, Fernández-Lopez JC, Bustabad S. Objetivos y metodología de la fase iii de BIOBADASER. Reumatol Clin. 2019;15:229–36.
Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):353–61.
Article
Google Scholar
Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, Chen L, Grijalva CG, Herrinton LJ. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics? Pharmacoepidemiol Drug Saf. 2012;21(5):524–34.
Article
CAS
Google Scholar
Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M. Reviewing the definition of “elderly”. Geriatr Gerontol Int. 2006;6(3):149–58.
Article
Google Scholar
Iwanaga N, Arima K, Terada K, Ueki Y, Horai Y, Suzuki T, Nakashima Y, Sy K, Ichinose K, Tamai M. Risk factors of adverse events during treatment in elderly patients with rheumatoid arthritis: an observational study. Int J Rheum Dis. 2017;20(3):346–52.
Article
CAS
Google Scholar
Singh S, Bajorek B: Defining ‘elderly’in clinical practice guidelines for pharmacotherapy. Pharm Pract. 2014;12:489–98.
Generali E, Scirè CA, Cantarini L, Selmi C. Sex differences in the treatment of psoriatic arthritis: a systematic literature review; 2016.
Google Scholar
Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin N Am. 2007;33(1):197–217.
Article
Google Scholar
Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheumatism. 1992;35(10):1117–25.
Article
CAS
Google Scholar
Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheumatism. 2007;56(6):1754–64.
Article
CAS
Google Scholar
Atzeni F, Masala IF, Di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Curr Opin Rheumatol. 2017;29(4):323–30.
Article
CAS
Google Scholar
Avila G, Alonso A, Pluma-Sanjurjo A, Diaz C, Juverdeanu R, López-Lasanta M, Marsal S. Risk analysis of a first adverse event and recurrent infections during biological therapy in chronic inflammatory arthritis. Arthritis Rheumatol. 2014;475:66.
Google Scholar
2016 GdTdPE. Prevalencia de las enfermedades Reumáticas en población adulta en España. Estudio EPISER 2016. Madrid: Sociedad Española de Reumatología; 2018.
Google Scholar
Ishchenko A, Lories RJ. Safety and efficacy of biological disease-modifying antirheumatic drugs in older rheumatoid arthritis patients: staying the distance. Drugs Aging. 2016;33(6):387–98.
Article
CAS
Google Scholar
Levine ME. Modeling the rate of senescence: can estimated biological age predict mortality more accurately than chronological age? J Gerontol Ser A Biomed Sci Med Sci. 2012;68(6):667–74.
Article
Google Scholar
Xue Q-L. The frailty syndrome: definition and natural history. Clin Geriatr Med. 2011;27(1):1–15.
Article
CAS
Google Scholar